<DOC>
	<DOCNO>NCT00000801</DOCNO>
	<brief_summary>To estimate response rate , overall disease-free survival , toxicity , factor associate outcome , effect quality life patient AIDS-related primary CNS lymphoma treat CHOD ( cyclophosphamide , doxorubicin , vincristine , dexamethasone ) plus filgrastim ( granulocyte-colony stimulating factor ; G-CSF ) external beam irradiation . To determine clinical marker present patient population . Combined modality therapy may prove benefit patient AIDS-related primary CNS lymphoma .</brief_summary>
	<brief_title>Phase II Trial Sequential Chemotherapy Radiotherapy AIDS-Related Primary Central Nervous System Lymphoma</brief_title>
	<detailed_description>Combined modality therapy may prove benefit patient AIDS-related primary CNS lymphoma . Patients upon stag workup find without systemic involvement undergo one cycle chemotherapy cyclophosphamide , doxorubicin , vincristine , dexamethasone , G-CSF . Cyclophosphamide , doxorubicin , vincristine administer intravenously day 1 . Dexamethasone administer intravenously day 1 orally thereafter gradual discontinuation . G-CSF administer subcutaneously daily begin day 2 continue total 10 day blood count recover acceptable level . Patients evidence cancer cell cerebrospinal fluid ( CSF ) receive chemotherapy intrathecal cytarabine twice weekly evidence cancer cell find CSF , weekly 6 week , monthly 10 month . Seven ten day follow completion one cycle chemotherapy , patient undergo radiotherapy brain dose 2.5 Gy daily 5 day per week approximately 4 week . Total dose whole brain meninges 30.0 Gy 12 fraction , total dose primary boost volume 10.0 Gy 4 fraction . During therapy , blood drawn weekly brain scan perform every 3-12 week . An initial CSF sample obtain lumbar puncture .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis Bactrim , dapsone , aerosolized pentamidine . Oral candidiasis prophylaxis fluconazole , ketoconazole , clotrimazole oral troche . Antiretroviral agent available therapy IND . MAI prophylaxis rifabutin ( patient CD4 count &lt; 100 cells/mm3 ) . Patients must : HIV infection . Primary CNS lymphoma NO systemic involvement . Prior Medication : Allowed : Prior corticosteroid . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Concomitant malignancy Kaposi 's sarcoma , curatively treat carcinoma situ cervix , squamous basal cell carcinoma skin . Active uncontrolled infection . Renal failure , active nonmalignant duodenal ulcer , uncontrolled diabetes mellitus , serious medical condition would preclude aggressive cytotoxic chemotherapy administration . Active heart disease ( congestive heart failure heart block great first degree EKG ) . Concurrent Medication : Excluded : Any investigational agent antiretroviral agent available therapy IND . Patients follow prior condition exclude : No prior malignancy Kaposi 's sarcoma , curatively treat carcinoma situ cervix , squamous cell basal cell carcinoma skin . No new infectious complication within past 2 week require change antibiotic . History myocardial infarction within past 3 month . Prior Medication : Excluded : Prior chemotherapy Kaposi 's sarcoma .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Vincristine</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Granulocyte Colony-Stimulating Factor</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents , Combined</keyword>
	<keyword>Brain Neoplasms</keyword>
	<keyword>Lymphoma , High-Grade</keyword>
	<keyword>Lymphoma , Intermediate-Grade</keyword>
</DOC>